PMD Device Solutions

PMDS has acquired the key assets of Coala Life for the purchase price of 3.6 MSEK with operational control passing to CEO Myles Murray as of signing.

Through the signing of the transfer agreement, PMDS will continue to focus its European business on growing accounts for RespiraSense and likewise to focus the US business on growing Coala’s offering. During the next 6-9 months, PMDS will evaluate its 2026 financial Annual Recurring Revenue target and adjust it to match the new sales potential of the group.

PMDS plans to include key developments of the number of patients per month in quarterly reports going forward, in addition to processing existing financial targets.

“I want to highlight my gratitude to the Coala team for their support with our due diligence. They have developed a very capable team and culture across Billing, Finance, Clinical Operations, Quality, and Sales, with significant learnings of what it takes to succeed. Today, approximately 1,400 patients per month are billed across a total of 15 clinics. The core clinics have the potential to generate over 5,000 patients per month. These represent the most reliable clinics for the business today. There is significant growth opportunity within these core clinics.”

“This immediate focus is to strengthen the foundation of the business, with the goal of achieving US operational profitability within Q2 2024. This will be achieved by implementing operational efficiencies while growing existing core accounts to their full potential.” Says Myles Murray

“We are greatful also to the Trustee and lawfirm Lindskog Malmström for their work in assisting with the evaluation and signing of the acquisition opportunity.”